Related Experiment Videos
[Estrogens and progestins in hormone replacement therapy in menopause]
1Laboratorio di Epidemiologia Generale, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Istituto di Statistica Medica e Biometria, Università, Milano.
Recenti Progressi in Medicina
|April 26, 2001
Summary
Hormone replacement therapy using estrogens alone increases endometrial cancer risk. However, combined estrogen-progestin therapy does not significantly raise this risk if progestins are used for at least 10 days, but may increase breast cancer incidence.
Area of Science:
- Gynecology
- Oncology
- Endocrinology
Context:
- Menopause hormone therapy (HT) is widely used to manage menopausal symptoms.
- Estrogen-only therapy is associated with increased endometrial cancer risk.
- Combined hormone therapy (estrogen-progestin) is an alternative for women with a uterus.
Purpose:
- To evaluate the association between hormone replacement therapy (HRT) formulations and the risk of endometrial and breast cancer.
- To compare the cancer risks associated with estrogen-only versus combined estrogen-progestin therapy in postmenopausal women.
Summary:
- Estrogen-only hormone replacement therapy (HRT) is linked to a higher risk of endometrial cancer.
- Combined HRT, including progestins for over 10-14 days per cycle, shows no significant increase in endometrial cancer risk.
- Combined HRT may be associated with a greater risk of breast cancer incidence compared to estrogen-only therapy.
Impact:
- Findings inform clinical decisions regarding HRT selection for menopausal women.
- Highlights the importance of progestin use in mitigating endometrial cancer risk with combined HRT.
- Suggests a potential increased breast cancer risk with combined HRT, warranting further investigation and patient counseling.